{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:59:53Z","timestamp":1764691193265,"version":"3.46.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"San Francisco Department of Public Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Linezolid is recommended for the treatment of rifampin-resistant tuberculosis (TB), but its role in rifampin-susceptible TB (RS-TB) is less understood. In 45 RS-TB patients treated with linezolid, 8 stopped due to adverse events, most commonly cytopenias. Further research is needed on linezolid efficacy, dosing, and adverse event management in RS-TB.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf714","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:57:55Z","timestamp":1764075475000},"source":"Crossref","is-referenced-by-count":0,"title":["Experience with Linezolid for the Treatment of Rifampin-Susceptible Tuberculosis in San Francisco"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6568-5213","authenticated-orcid":false,"given":"Janice K","family":"Louie","sequence":"first","affiliation":[{"name":"Tuberculosis Prevention and Control Program, San Francisco Department of Public Health , San Francisco, California ,","place":["USA"]},{"name":"Department of Medicine, University of California , San Francisco, San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo E","family":"Vel\u00e1squez","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases, and Global Medicine, University of California , San Francisco, San Francisco, California ,","place":["USA"]},{"name":"UCSF Center for Tuberculosis, Institute for Global Health Sciences, University of California , San Francisco, San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Phillips","sequence":"additional","affiliation":[{"name":"Tuberculosis Prevention and Control Program, San Francisco Department of Public Health , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-9704","authenticated-orcid":false,"given":"John D","family":"Szumowski","sequence":"additional","affiliation":[{"name":"Tuberculosis Prevention and Control Program, San Francisco Department of Public Health , San Francisco, California ,","place":["USA"]},{"name":"Department of Medicine, University of California , San Francisco, San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2025120210562189700_ofaf714-B1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025120210562189700_ofaf714-B2","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant Tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2025120210562189700_ofaf714-B3","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant Tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2025120210562189700_ofaf714-B4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral regimens for rifampin-resistant, fluoroquinolone-susceptible Tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N Engl J Med"},{"author":"Conradie","key":"2025120210562189700_ofaf714-B5"},{"key":"2025120210562189700_ofaf714-B6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S2213-2600(25)00194-8","article-title":"Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial","volume":"13","author":"Guglielmetti","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2025120210562189700_ofaf714-B7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5588\/ijtld.16.0113","article-title":"Evolving strategies for dose optimization of linezolid for treatment of tuberculosis","volume":"20","author":"Nuermberger","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025120210562189700_ofaf714-B8","doi-asserted-by":"crossref","first-page":"ii17","DOI":"10.1093\/jac\/dkg248","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025120210562189700_ofaf714-B9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant Tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120210562189700_ofaf714-B10"},{"key":"2025120210562189700_ofaf714-B11"},{"key":"2025120210562189700_ofaf714-B12","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease control and prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B13"},{"key":"2025120210562189700_ofaf714-B14"},{"key":"2025120210562189700_ofaf714-B15","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant Tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025120210562189700_ofaf714-B16"},{"key":"2025120210562189700_ofaf714-B17","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025120210562189700_ofaf714-B18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant Tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B19"},{"key":"2025120210562189700_ofaf714-B20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/cid\/ciac867","article-title":"Adverse events associated with treatment for pan-susceptible Tuberculosis in San Francisco","volume":"76","author":"Louie","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B21","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/cid\/ciz306","article-title":"Tuberculosis in older adults: seattle and king county, Washington","volume":"70","author":"Gardner Toren","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant Tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"key":"2025120210562189700_ofaf714-B23","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/cid\/ciab699","article-title":"Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant Tuberculosis","volume":"74","author":"Imperial","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/cid\/ciaf027","article-title":"Linezolid dosing and pharmacokinetics in north American patients with Tuberculosis","volume":"81","author":"Maranchick","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B25","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant Tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120210562189700_ofaf714-B26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1056\/NEJMc2119461","article-title":"Pretomanid in the treatment of patients with Tuberculosis in the United States","volume":"387","author":"Goswami","year":"2022","journal-title":"N Engl J Med"},{"key":"2025120210562189700_ofaf714-B27","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/pharmaceutics16060818","article-title":"New oxazolidinones for Tuberculosis: are novel treatments on the horizon?","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025120210562189700_ofaf714-B28","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S1473-3099(25)00213-0","article-title":"Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial","volume":"25","author":"Heinrich","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120210562189700_ofaf714-B29","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1473-3099(25)00289-0","article-title":"Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial","volume":"25","author":"Minja","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025120210562189700_ofaf714-B30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13063-025-08973-w","article-title":"ACTG a5409 (RAD-TB): study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis","volume":"26","author":"Harrison","year":"2025","journal-title":"Trials"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf714\/65534393\/ofaf714.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf714\/65534393\/ofaf714.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/12\/ofaf714\/65534393\/ofaf714.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T15:56:32Z","timestamp":1764690992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf714\/8342991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf714","relation":{},"ISSN":["2328-8957"],"issn-type":[{"type":"electronic","value":"2328-8957"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,26]]},"article-number":"ofaf714"}}